Pfizer Licenses Nutrition 21’s Chromax In Patent Claim Settlement
This article was originally published in The Tan Sheet
The settlement terms are confidential, but Pfizer “acknowledged the validity of Nutrition 21’s asserted patents” and the Centrum line “may continue to use chromium picolinate,” Nutrition 21 says. The firms agreed as attorneys prepared to begin questioning a pool of potential jurors for the trial.
You may also be interested in...
Michael Satow, formerly of JDS Pharmaceuticals, tries his hand in the nutritional ingredients space as CEO of Nutrition 21. In a recent interview, Satow discussed his initial impressions of the industry and what potential he sees in a portfolio that includes Chromax chromium picolinate.
Ingredient developer Nutrition 21 filed for Chapter 11 bankruptcy protection and is soliciting bidders for its assets following an unsuccessful transition into the finished nutritional product space.
Reps. Brendan Boyle and Darin LaHood introduce Dietary Supplement Tax Fairness Ac to amend Internal Revenue Code to include some supplement products as qualified medical expenses.